The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
VA Office of Research and Development
Tizona Therapeutics, Inc
Essen Biotech
IDEAYA Biosciences
Weill Medical College of Cornell University
University of Kentucky
University of California, San Francisco
University of California, San Francisco
University of Wisconsin, Madison
Twinpig Biolab, Inc.
Jonsson Comprehensive Cancer Center
BioXcel Therapeutics Inc
Amgen
Maastricht University Medical Center
OHSU Knight Cancer Institute
Lava Therapeutics
Peter MacCallum Cancer Centre, Australia
University of California, San Francisco
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Icahn School of Medicine at Mount Sinai
University of Southern California
Merck Sharp & Dohme LLC
Seagen Inc.
CHU de Quebec-Universite Laval
Carisma Therapeutics Inc
University of California, San Francisco
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC
Advaxis, Inc.
NGM Biopharmaceuticals, Inc
OHSU Knight Cancer Institute
Evopoint Biosciences Inc.
University of Wisconsin, Madison
Kineta Inc.
Xencor, Inc.
Portland VA Medical Center
Portland VA Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IRCCS San Raffaele